病理性缩和心脏间隙. 纤维化和氨酸 - - ангиотензин - - 阿尔多斯特系统
1Division of Cardiology, University of Missouri-Columbia, Columbia 65212.
Circulation
|June 1, 1991
概括
左心室缩 (LVH) 可能导致心力衰竭. 纤维化是由心脏纤维细胞驱动的,受高血压和阿尔多斯激素的影响,导致心肌硬和功能障碍,这表明新的治疗点.
科学领域:
- 心脏病学 心脏病学
- 病理学 病理学 病理学
- 生物化学 生物化学
背景情况:
- 左心室缩 (LVH) 是心肌衰竭的主要危险因素.
- 背后的病理机制 LVH诱导的心脏功能障碍尚未完全理解.
- 心肌结构的异常,特别是纤维化,有助于心脏功能受损.
研究的目的:
- 研究非肌细胞细胞,特别是心脏纤维细胞在病理性LVH发展中的作用.
- 在LVH的背景下阐明肌细胞和非肌细胞细胞生长之间的关系.
- 在高血压心脏中识别导致间歇性和周血管纤维化的因素.
主要方法:
- 在动物模型中实验性高血压的体内研究中使用.
- 研究了动脉动素II和阿尔多斯的不同血度的影响.
- 采用形态测量和形态学分析来评估心肌结构和纤维化.
主要成果:
- 在实验性高血压中证明了肌细胞和非肌细胞的独立生长.
- 在过度缩小的心室中发现了纤维状原蛋白 (纤维化) 的异常积累.
- 发现动脉高血压和阿尔多激素升高与心脏纤维细胞激活和心肌结构异质性有关.
结论:
- 非肌细胞细胞,特别是心脏纤维细胞,是病理性LVH的关键决定因素.
- 升高的冠状动脉 perfusion 压力和阿尔多素有助于心脏纤维化和心室功能障碍.
- 需要对纤维细胞反应机制进行进一步的研究,以制定预防和逆转病态LVH的策略.
相关概念视频
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...